Enavate Sciences GP, LLC
Performance · Fund vs SPY
Cumulative return · quarterly snapshotsCoverage 100%. 4 quarters of 2025 measured against SPY adj-close benchmark.
Why follow Enavate Sciences GP, LLC right now?
Enavate Sciences GP, LLC reported $352M in 13F-disclosed assets across just 7 positions as of 31 March 2026, a concentration profile that leaves the portfolio highly exposed to single-name binary events. The top three holdings — Sionna Therapeutics (28.3%), Immunome (22.5%), and Zenas BioPharma (21.8%) — account for roughly 72.6% of disclosed value, all in clinical-stage biotechnology. Compass Therapeutics adds a further 11.7%.
Quarterly returns over the trailing four periods show significant variance: +155.2% in Q1 2026 and +143.5% in Q4 2025 against SPY's +17.6% and +17.7% respectively, but -6.3% in Q2 2025 when SPY returned +6.1%. Past performance is not indicative of future results.
Generated from public SEC filings. Not investment advice.…
Read the full 113-word brief. Pro members get the complete editorial analysis on every curated manager, plus Sunday Pulse + Stock Picks.
Unlock with Pro — $9.99/moTop holdings · current snapshot
Source: 13F-HRRecent trades · Last 90 days
Convergence · Enavate Sciences GP, LLC
Source data: SEC EDGAR · 13F-HR filings · Performance through 2026-03-31 · Last refreshed 13:47 UTC.